{"nctId":"NCT02573324","briefTitle":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","startDateStruct":{"date":"2015-01-04","type":"ACTUAL"},"conditions":["Glioblastoma","Gliosarcoma"],"count":691,"armGroups":[{"label":"Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ)","type":"EXPERIMENTAL","interventionNames":["Drug: Temozolomide","Drug: Depatuxizumab mafodotin","Radiation: Radiation"]},{"label":"Placebo, Radiation and TMZ","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Temozolomide","Radiation: Radiation","Drug: Placebo for ABT-414"]},{"label":"Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ","type":"EXPERIMENTAL","interventionNames":["Drug: Temozolomide","Drug: Depatuxizumab mafodotin","Radiation: Radiation"]}],"interventions":[{"name":"Temozolomide","otherNames":[]},{"name":"Depatuxizumab mafodotin","otherNames":["ABT-414"]},{"name":"Radiation","otherNames":[]},{"name":"Placebo for ABT-414","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have a clinical diagnosis of glioblastoma (GBM).\n* Must have a confirmed epidermal growth factor receptor amplification in tumor tissue.\n* Must have a Karnofsky Performance Status (KPS) \\>= 70 at assessment \\<= 14 days prior to randomization (N/A to the sub-study).\n* Must have recovered from effects of surgery, postoperative infection and other complications of surgery.\n* Must have adequate bone marrow, renal, and hepatic function (For the sub-study, the participant must have adequate bone marrow and renal function and have mild-to-moderate hepatic impairment).\n\nExclusion Criteria:\n\n* Multifocal, recurrent or metastatic GBM or gliomatosis cerebri (For the sub-study, the participant can have multifocal GBM and glimatosis cerebri but can't have recurrent or metastatic GBM).\n* Prior chemo therapy or radiosensitizer for head and neck cancer.\n* Prior radiotherapy to the head or neck in overlap of radiation fields.\n* Prior therapy for glioblastoma or other invasive malignancy.\n* Prior, concomitant or planned treatment with Novo Tumor Treatment Fields (Novo-TTF), EGFR-targeted therapy, bevacizumab, Gliadel wafers or other intratumoral or intracavity anti-neoplastic therapy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7","spread":null},{"groupId":"OG001","value":"18.9","spread":null}]}]}]},{"type":"SECONDARY","title":"OS for the O6-methylguaninemethlytransferese (MGMT) Unmethylated Group","description":"Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause.\n\nUnmethylated MGMT promoter is associated with a worse prognosis in GBM","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"16.1","spread":null}]}]}]},{"type":"SECONDARY","title":"OS for the MGMT Methylated Group","description":"Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"25.4","spread":null}]}]}]},{"type":"SECONDARY","title":"OS for the Epidermal Growth Factor Receptor (EGFR)vIII-Mutated Tumor Subgroup","description":"Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"19.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS will be defined as the number of days from the date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria (see Wen et al. J Clin Oncol. 2010 Apr 10;28(11):1963-72) or to the date of death, if disease progression does not occur.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS for EGFRvIII-Mutated Tumor Subgroup","description":"PFS will be defined as the number of days from the date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria or to the date of death, if disease progression does not occur.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Deterioration Free Survival in M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) Symptom Severity Score","description":"The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It consists of 22 symptom items and 6 interference items, each rated from 0 to 10. MDASI-BT symptom severity score is defined as average over 13 core symptom items and 9 brain tumor symptom items, with a total score of 0 to 10, with higher score indicating worse symptoms/interference. Changes in symptom severity score were classified into 3 categories: improved (≤ -1), stable (\\> -1 and \\< 1), and deteriorated (≥ 1). Deterioration is defined as satisfying the deterioration criteria (i.e., increase in symptom severity score by ≥ 1 unit) without further improvement (i.e., failing to satisfy deterioration criteria) within 8 weeks or occurrence of death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Deterioration Free Survival in MDASI-BT Symptom Interference Score","description":"The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It consists of 22 symptom items and 6 interference items, each rated from 0 to 10. MDASI-BT symptom interference score is defined as an average of 6 interference items, with a total score of 0 to 10, where higher scores indicate worse interference. Changes in symptom interference score were classified into 3 categories: improved (≤ -1), stable (\\> -1 and \\< 1), and deteriorated (≥ 1). Deterioration is defined as satisfying the deterioration criteria (i.e., increase in symptom interference score by ≥ 1 unit) without further improvement (i.e., failing to satisfy deterioration criteria) within 8 weeks or occurrence of death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Deterioration Free Survival in Neurocognitive Functioning on the Hopkins Verbal Learning Test Revised (HVLT-R) Total Recall Score","description":"The HVLT-R consists of 3 parts. Free call has a range of 0 to 36, delayed recall has a range from 0 to 12, and delayed recognition has a range of -12 to 12. Higher scores indicating better function in all 3 parts. When scoring the HVLT-R, the 3 learning trials are combined to calculate a total recall score (range -12 to 60). Deterioration is defined as satisfying the deterioration criteria (i.e., decrease in HVLT-R total recall score by 5 units) without further improvement within 8 weeks or occurrence of death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":335},"commonTop":["FATIGUE","THROMBOCYTOPENIA","NAUSEA","KERATOPATHY","CONSTIPATION"]}}}